Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis

Autor:	Beth S. Gottlieb, Yuliya Lokhnygina, Kristi Prather, Michael L. Miller, James D Birmingham, Stacey E. Tarvin, Marilynn Punaro, Lisa Imundo, Steven J. Spalding, Lawrence S. Zemel, David D. Sherry, Carol A. Wallace, Yukiko Kimura, Kathleen M. O'Neil, Natasha M. Ruth, James W. Verbsky, Diana Milojevic, Norman T. Ilowite, Melissa E. Elder, Nora G. Singer, Christy Sandborg, Laura E. Schanberg
Rok vydání:	2014
Předmět:	medicine.medical_specialty business.industry Immunology Placebo-controlled study Arthritis medicine.disease law.invention Double blind Rilonacept Antirheumatic Agents Rheumatology Randomized controlled trial Multicenter study law Internal medicine Physical therapy Immunology and Allergy Medicine Juvenile business medicine.drug
Zdroj:	Arthritis & Rheumatology. 66:2570-2579
ISSN:	2326-5191
DOI:	10.1002/art.38699
Popis:	Background Interleukin-1 plays a pivotal role in in the pathogenesis of systemic juvenile idiopathic arthritis (sJIA). We assessed the efficacy and safety of rilonacept (IL-1 trap), an IL-1 inhibitor, in a randomized, double-blind, placebo-controlled trial.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::27840dc604352c1dfde837cb065043a2 https://doi.org/10.1002/art.38699 Zobrazit plný text záznamu Plný text